Table 1 Pathophysiological data for Dahl salt-sensitive rats treated with amlodipine or azelnidipine

From: Azelnidipine attenuates glomerular damage in Dahl salt-sensitive rats by suppressing sympathetic nerve activity

Group

DN (n=7)

DH (n=7)

DH-Amlo (n=7)

DH-Azel (n=7)

BW (g)

343±7

350±10

328±5

332±6

SBP (mm Hg)

124±4

201±5a

156±7a,b

156±7a,b

HR (b.p.m.)

367±9

421±5a

406±10a

353±4b,c

Kidney NE (ng g−1 tissue)

0.65±0.06

1.55±0.10a

1.03±0.06a,b

0.76±0.06b,c

Kidney AGT mRNA

1.00±0.05

2.11±0.19a

1.43±0.09a,b

1.39±0.13a,b

Kidney AT1R mRNA

1.00±0.04

0.71±0.10a

0.86±0.08a

0.81±0.05a

  1. Data are presented as mean±s.e.m.
  2. AGT, angiotensinogen; AT1R, angiotensin type 1 receptor; BW, body weight; DN, untreated Dahl salt-sensitive hypertensive rats fed a 0.9% salt diet; DH, untreated Dahl salt-sensitive hypertensive rats fed an 8% salt diet; DH-Amlo, Dahl salt-sensitive hypertensive rats treated with amlodipine (1.0 mg kg–1 per day); DH-Azel, Dahl salt-sensitive hypertensive rats treated with azelnidipine (3.0 mg kg–1 per day); HR, heart rate; NE, norepinephrine concentration; SBP, systolic blood pressure.
  3. aP<0.05 vs. DN; bP<0.05 vs. DH; cP<0.05 vs. DH-Amlo.
Back to article page